发明名称 Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
摘要 The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive CNS noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive CNS noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens.
申请公布号 US9364515(B2) 申请公布日期 2016.06.14
申请号 US201414447247 申请日期 2014.07.30
申请人 VeroScience LLC 发明人 Cincotta Anthony H.
分类号 A23L1/30;A61K38/16;A23L1/29;A61K31/198;A61K31/20;A61K31/201;A61K31/202;A61K31/405;A61K31/70;A23L1/304;A23L1/0522;A23L1/09 主分类号 A23L1/30
代理机构 Fish & Richardson P.C. 代理人 Fish & Richardson P.C.
主权项 1. A food product effective for treating a patient suffering from a condition selected from the group consisting of metabolic syndrome, obesity, type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and procoagulative state, said food product comprising: (a) nutrients that decrease overactive CNS noradrenergic tone selected from the group consisting of pantethine, neuronal noradrenaline synthesis inhibitors, neuronal postsynaptic noradrenergic receptor blockers, neuronal presynaptic noradrenaline reuptake enhancers, neuronal presynaptic noradrenaline receptor stimulators, neuronal presynaptic noradrenaline release inhibitors, noradrenaline degradation enzyme stimulators, neuronal postsynaptic noradrenaline signal transduction inhibitors, and combinations thereof; and (b) nutrients that increase dopaminergic tone selected from the group consisting of L-DOPA, neuronal dopamine synthesis stimulators, neuronal postsynaptic dopaminergic receptor stimulators, neuronal presynaptic dopamine reuptake inhibitors, neuronal presynaptic dopamine receptor blockers, neuronal presynaptic dopamine release enhancers, dopamine degradation enzyme inhibitors, neuronal postsynaptic dopamine signal transduction stimulators, and combinations thereof.
地址 Tiverton RI US